Congenital Metabolic Bone Disorders as a Cause of Bone Fragility.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Sep 2021
Historique:
received: 07 09 2021
revised: 21 09 2021
accepted: 22 09 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 29 10 2021
Statut: epublish

Résumé

Bone fragility is a pathological condition caused by altered homeostasis of the mineralized bone mass with deterioration of the microarchitecture of the bone tissue, which results in a reduction of bone strength and an increased risk of fracture, even in the absence of high-impact trauma. The most common cause of bone fragility is primary osteoporosis in the elderly. However, bone fragility can manifest at any age, within the context of a wide spectrum of congenital rare bone metabolic diseases in which the inherited genetic defect alters correct bone modeling and remodeling at different points and aspects of bone synthesis and/or bone resorption, leading to defective bone tissue highly prone to long bone bowing, stress fractures and pseudofractures, and/or fragility fractures. To date, over 100 different Mendelian-inherited metabolic bone disorders have been identified and included in the OMIM database, associated with germinal heterozygote, compound heterozygote, or homozygote mutations, affecting over 80 different genes involved in the regulation of bone and mineral metabolism. This manuscript reviews clinical bone phenotypes, and the associated bone fragility in rare congenital metabolic bone disorders, following a disease taxonomic classification based on deranged bone metabolic activity.

Identifiants

pubmed: 34638624
pii: ijms221910281
doi: 10.3390/ijms221910281
pmc: PMC8509040
pii:
doi:

Substances chimiques

Extracellular Matrix Proteins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Rambam Maimonides Med J. 2012 Apr 30;3(2):e0013
pubmed: 23908837
J Bone Miner Res. 2014 Apr;29(4):830-42
pubmed: 24014480
Hum Mol Genet. 2010 Jan 15;19(2):223-34
pubmed: 19846465
J Biol Phys. 2008 Apr;34(1-2):39-49
pubmed: 19669491
J Biol Chem. 2010 Aug 13;285(33):25103-8
pubmed: 20501658
Ann N Y Acad Sci. 2006 Dec;1092:385-96
pubmed: 17308163
Cell Biosci. 2013 Jan 15;3(1):4
pubmed: 23321200
Clin Cases Miner Bone Metab. 2011 Sep;8(3):9-13
pubmed: 22461821
J Nippon Med Sch. 2010 Feb;77(1):4-12
pubmed: 20154452
Nat Commun. 2016 Jul 06;7:11920
pubmed: 27380894
Physiology (Bethesda). 2016 May;31(3):233-45
pubmed: 27053737
Front Immunol. 2017 Aug 03;8:897
pubmed: 28824625
Am J Med Genet. 1999 Jan 1;82(1):1-5
pubmed: 9916834
Int J Mol Sci. 2021 Jan 10;22(2):
pubmed: 33435159
J Biol Chem. 2011 Jun 3;286(22):19489-500
pubmed: 21471202
BMC Pediatr. 2019 Feb 27;19(1):68
pubmed: 30813920
Mol Cells. 2017 Oct;40(10):706-713
pubmed: 29047262
Cold Spring Harb Perspect Biol. 2016 Jun 01;8(6):
pubmed: 27252362
J Biol Chem. 2006 Nov 3;281(44):33814-24
pubmed: 16959767
Eur J Endocrinol. 2015 Sep;173(3):R131-51
pubmed: 25971649
Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12):
pubmed: 23209148
Horm Res Paediatr. 2020;93(3):182-196
pubmed: 32756064
PLoS Genet. 2016 Jul 21;12(7):e1006156
pubmed: 27441836
J Clin Endocrinol Metab. 2017 Jan 1;102(1):251-258
pubmed: 27813708
Am J Med Genet A. 2019 Dec;179(12):2393-2419
pubmed: 31633310
Am J Hum Genet. 2019 Oct 3;105(4):836-843
pubmed: 31564437
Int J Mol Sci. 2021 Jan 29;22(3):
pubmed: 33572704
Am J Hum Genet. 2020 Nov 5;107(5):989-999
pubmed: 33053334
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3111-3123
pubmed: 28655174
FASEB J. 2018 May;32(5):2878-2890
pubmed: 29401593
Osteoporos Int. 2020 Feb;31(2):327-333
pubmed: 31720712
J Bone Miner Res. 2011 Feb;26(2):229-38
pubmed: 21254230
Front Endocrinol (Lausanne). 2017 Jan 16;7:172
pubmed: 28138323
Osteoporos Int. 2015 Oct;26(10):2529-58
pubmed: 26070300
Eur J Rheumatol. 2017 Mar;4(1):46-56
pubmed: 28293453
J Bone Miner Res. 2002 Jan;17(1):77-90
pubmed: 11771672
Bone Res. 2013 Mar 29;1(1):11-26
pubmed: 26273491
Biomed Res Int. 2015;2015:421746
pubmed: 26247020
J Biol Chem. 2007 Jul 27;282(30):22062-71
pubmed: 17522057
Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):701-22
pubmed: 19028353
Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(4):130-43
pubmed: 24727937
Cell Rep. 2021 Apr 20;35(3):109015
pubmed: 33882302

Auteurs

Francesca Marini (F)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50139 Florence, Italy.
F.I.R.M.O. Fondazione Italiana per la Ricerca sulle Malattie dell'Osso, Italian Foundation for the Research on Bone Diseases, 50141 Florence, Italy.

Francesca Giusti (F)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50139 Florence, Italy.

Teresa Iantomasi (T)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50139 Florence, Italy.

Maria Luisa Brandi (ML)

F.I.R.M.O. Fondazione Italiana per la Ricerca sulle Malattie dell'Osso, Italian Foundation for the Research on Bone Diseases, 50141 Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH